Wyeth Japan Appoints New President
This article was originally published in PharmAsia News
Executive Summary
Michael Goettler took over as Wyeth Japan president Sept. 17; he replaced Susumu Kurata, who will remain as an executive director until Sept. 30. At the age of 41, Goettler worked at Hoechst AG, Aventis Pharmaceutical before he became marketing division head for Sanofi Aventis in 2005. He later served as the vice president for Wyeth Pharmaceuticals' biopharma division, and in 2008 he assumed the role of marketing vice president in charge of opioid constipation drug Relistor (methylnaltrexone). (Click here for more - Japanese language
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.